Evidence map›Paper›PMID 38566199›Full record

ReviewJournal of hematology & oncology2024

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy.

Qiang Lu, Dongquan Kou, Shenghan Lou, Milad Ashrafizadeh, Amir Reza Aref, Israel Canadas, Yu Tian, Xiaojia Niu, Yuzhuo Wang, Pedram Torabian and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 1 pooled it
56.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 1 synthesis or guideline pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 4 countries.

Qiang Lu *Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, 569 Xinsi Road, Xi'an, 710038, China.
Dongquan Kou *Department of Rehabilitation Medicine, Chongqing Public Health Medical Center, Chongqing, China.
Shenghan Lou *Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
Milad AshrafizadehDepartment of General Surgery, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Amir Reza ArefXsphera Biosciences, Translational Medicine Group, 6 Tide Street, Boston, MA, 02210, USA.
Israel CanadasBlood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Yu TianSchool of Public Health, Benedictine University, Lisle, USA.
Xiaojia NiuDepartment of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H3Z6, Canada.
Yuzhuo WangDepartment of Urologic Sciences and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H3Z6, Canada.
Pedram TorabianCumming School of Medicine, Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, T2N 4Z6, Canada.
Lingzhi WangNUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
Gautam SethiNUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore. phcgs@nus.edu.sg.
Vinay TergaonkarLaboratory of NF-κB Signalling, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, 138673, Singapore, Republic of Singapore.
Franklin TayThe Graduate School, Augusta University, 30912, Augusta, GA, USA.
Zhennan YuanDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. yuanzhennan123@hrbmu.edu.cn.
Peng HanDepartment of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China. leospiv@hrbmu.edu.cn.
Third Affiliated Hospital of Harbin Medical University · CNNational University of Singapore · SGUniversity of British Columbia · CAAir Force Medical University · CNBenedictine University · USChongqing Public Health Medical Center · CNDana-Farber Cancer Institute · USFox Chase Cancer Center · USInstitute of Molecular and Cell Biology · SGThe First Affiliated Hospital, Sun Yat-sen University · CNThe Graduate Center, CUNY · USUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in the clinical delivery of immunomodulatory compounds. The tumor microenvironment (TME), comprising macrophages, fibroblasts, and immune cells, plays a crucial role in immune response modulation. Nanoparticles, engineered to reshape the TME, have shown promising results in enhancing immunotherapy by facilitating targeted delivery and immune modulation. These nanoparticles can suppress fibroblast activation, promote M1 macrophage polarization, aid dendritic cell maturation, and encourage T cell infiltration. Biomimetic nanoparticles further enhance immunotherapy by increasing the internalization of immunomodulatory agents in immune cells such as dendritic cells. Moreover, exosomes, whether naturally secreted by cells in the body or bioengineered, have been explored to regulate the TME and immune-related cells to affect cancer immunotherapy. Stimuli-responsive nanocarriers, activated by pH, redox, and light conditions, exhibit the potential to accelerate immunotherapy. The co-application of nanoparticles with immune checkpoint inhibitors is an emerging strategy to boost anti-tumor immunity. With their ability to induce long-term immunity, nanoarchitectures are promising structures in vaccine development. This review underscores the critical role of nanoparticles in overcoming current challenges and driving the advancement of cancer immunotherapy and TME modification.

Indexed as

NanoparticlesNeoplasmsCell DifferentiationHumansImmunotherapyTumor MicroenvironmentBioengineered nanostructures; cancer immunotherapyImmune evasion nanoparticlesTumor microenvironment

Identifiers

PMID38566199
PMCPMC10986145
OpenAlexW4393397203

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.